

### AMENDMENTS TO THE CLAIMS

1.-72. (Canceled)

73. (Currently amended) A method of ~~regulating~~ inhibiting hematopoietic cell survival ~~comprising~~ consisting of:

~~targeting a mutation to~~ mutating at least one of the residues of a binding motif ~~capable of binding a cytoplasmic protein~~ of a GM-CSF/IL-3/IL-5 receptor of a hematopoietic cell, wherein the receptor has a beta-chain having an amino acid sequence according to SEQ ID NO: 1 and the binding motif has the amino acid sequence <sup>598</sup>HSRSLP<sup>603</sup>, ~~wherein at least one of the residues of the binding motif is capable of being mutated.~~

74. (Currently amended) A method according to claim 73, wherein a serine ~~or threonine residue~~ corresponds to a serine residue at position 601 is mutated.

75. (Currently amended) A method according to claim 73, wherein at least two (2) amino acids at any position from 598-603 are ~~serine~~ mutated.

76. (Previously presented) A method according to claim 73, wherein the hematopoietic cell is a leukocyte.

77. (Previously presented) A method according to claim 73, wherein the mutation of the binding motif inhibits phosphorylation of the binding motif.

78. (Currently amended) A method according to claim 73, wherein the mutation of the at least a serine residue at position 601 is targeted and mutation of the residue inhibits phosphorylation of the binding motif.

79. (Currently amended) A method according to claim 73, wherein mutation of at least two (2) amino acids at any position from 598-603 inhibits phosphorylation of the binding motif is targeted at residue 601.